Johnson Matthey Public Limited Company

Immunomolecular Therapeutics, Inc.

Xing Fu

Saroop Matharu

Jeremy Clinton Wilt

Rajesh Shukla

Albrecht Zumbrunn

Saroop Singh Matharu

The present invention provides methods of synthesizing D-&#x3b1;-methyldopa and L-&#x3b1;-methyldopa.

Methods for producing D-&#x3b1;-methyldopa

An alkyl ester of 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butyric acid, such as ethyl 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoate, is obtained by reacting an alkyl ester of 4-(5-amino-1-methyl-1H-benzo[d]imidazol-2-yl)butyric acid with 2-hydroxyacetaldehyde under reducing conditions.

Process for preparing alkyl esters of 4-(5-(bis(2-hydroxyethyl)amino-1-methyl-1H-benzo[D]imidazol-2-yl)butyric acid

Wet bendamustine hydrochloride monohydrate may be dried by a two stage process wherein rapid drying is first carried out to provide a partially dried product, which is then further dried using an inert gas of controlled relative humidity to yield dry bendamustine hydrochloride monohydrate.

Process for drying bendamustine hydrochloride monohydrate

A method of preparing a ribofuranose derivative essentially free of pyranose compounds includes a step of contacting a solution of MDR containing MDRP as an impurity in a solvent including methanol and/or tetrahydrofuran with at least one alkali metal periodate under conditions sufficient to oxidize at least a portion of the MDRP. MDR containing at most 5 wt % of MDRP based on the total weight of MDR and MDRP may be produced.

Growing community of inventors

Acton, MA, United States of America

Xing Fu